Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) is a clinical-stage biotechnology innovator developing targeted immunotherapies through its proprietary FHAB platform. This page serves as the definitive source for verified company announcements, including clinical trial updates, regulatory milestones, and strategic developments in immuno-oncology.
Investors and researchers will find timely updates on SONN's pipeline progress, including its lead candidates targeting cancer and immune-mediated conditions. Our curated news collection features press releases about FHAB technology advancements, partnership announcements, and financial disclosures – all essential for tracking this innovative biotech's trajectory.
The repository systematically organizes updates across key categories: new patent filings, preclinical data publications, Phase 1 trial results, and executive team developments. Each entry maintains strict editorial standards to ensure compliance with financial reporting regulations.
For those monitoring advancements in bispecific antibody therapies and tumor microenvironment modulation, this resource offers structured access to SONN's scientific and corporate developments. Bookmark this page for efficient tracking of how the company's platform-based approach translates to clinical progress and strategic positioning within the competitive oncology landscape.
Sonnet BioTherapeutics Holdings announced the clearance of IND for its lead asset, SON-1010, and the initiation of its first clinical trial for advanced solid tumors. The company aims to advance SON-080 into clinical studies by mid-2022 and plans non-human primate toxicity studies for SON-1210 soon. Financially, Sonnet reported $13.6 million in cash with R&D expenses rising to $6.4 million in Q2 2022, driven by increased operational activities. The decrease in general and administrative expenses to $1.9 million indicates ongoing cost management efforts.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced the initiation of a Phase 1 clinical trial for SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of SON-1010. The FHB technology targets tumors, potentially enhancing the efficacy and safety of immunotherapy. The trial, employing a 3+3 design, seeks to establish the maximum tolerated and recommended doses. Dr. Richard Kenney expressed optimism about the potential of SON-1010 to improve cytokine immunotherapy outcomes.
Sonnet BioTherapeutics Holdings, (NASDAQ:SONN) announced significant preclinical data for its bispecific interleukin candidates, SON-1010, SON-1210, and SON-1410, during the AACR Annual Meeting 2022. The studies demonstrated effective tumor growth reduction in a B16-F10 melanoma model, with 67% reduction for SON-1210 and 76% for SON-1410 at a 5µg dose. The company plans to initiate the first patient dosing for SON-1010, paving the way for further development of its bispecific candidates.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has received FDA clearance for its Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12), marking the company's first IND clearance. This enables the initiation of a Phase 1 trial aimed at evaluating the safety and efficacy of SON-1010 in adult oncology patients, expected to begin in Q2 2022. The trial will focus on safety, tolerability, and pharmacokinetics, utilizing a standard 3+3 oncology design to establish dosing parameters.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced that its preclinical data on Fully Human Albumin Binding candidates (SON-1010, SON-1210, SON-1410) will be presented at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The presentation will showcase an innovative platform for targeted delivery of bispecific interleukins to tumors. The session is scheduled for April 13, 2022, from 9:00 AM to 12:30 PM EDT. The company focuses on developing biologic drugs that improve therapeutic efficiency and safety.
Sonnet BioTherapeutics Holdings, with ticker SONN, announced progress in its clinical pipeline and financial results for Q1 FY 2022. The company is set to initiate clinical studies for SON-1010 and SON-080 in Q2 2022, alongside completing R&D for a toxicity study for SON-1210. Financially, Sonnet held $19.4 million in cash, with R&D expenses increasing to $4.3 million from $3.9 million year-over-year. The net loss for the quarter was $6.2 million, a slight increase compared to the previous year's loss of $5.9 million.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported its fiscal year 2021 results, highlighting significant advancements in its therapeutic pipeline. The company announced promising data from preclinical studies for SON-1010 and SON-080, along with the identification of a new bispecific candidate, SON-1410. Financially, Sonnet raised approximately $27.6 million through a public offering, ending the fiscal year with $27.6 million in cash. R&D expenses rose to $16.6 million, reflecting ongoing development efforts. The CEO expressed confidence in the company's growth trajectory for 2022.
Sonnet BioTherapeutics has selected a new candidate, SON-1410 (IL18-FHAB-IL12), for development after successful comparisons in a mouse melanoma study. This candidate, integrating Interleukins 18 and 12, aims to target melanoma and renal cancers. An IND submission is expected in 2022. The study showed significant tumor reduction compared to placebo, with promising immune responses. Following a recent $30 million financing, Sonnet is focused on advancing its immuno-oncology pipeline, with manufacturing processes for SON-1410 already in progress.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced a public offering of 35,294,117 shares at a price of $0.85 per share, projected to raise approximately $30 million before expenses. Each share comes with an investor warrant for one additional share at the same price. A 30-day over-allotment option for an additional 5,294,117 shares is available to underwriters. Funds will be allocated for research, clinical trials, and general corporate purposes. The offering is expected to close around August 24, 2021.
Sonnet BioTherapeutics (NASDAQ:SONN) reported its fiscal Q3 2021 results, noting progress on its Fully Human Albumin Binding (FHAB) drug pipeline. With IND submissions for SON-1010 and SON-080 anticipated by year-end 2021, the company is focused on increasing the efficacy of targeted therapies. The financing strategy generated $15.9 million through an at-the-market sale, enhancing R&D capabilities. As of June 30, 2021, cash on hand stood at $6 million, with R&D expenses rising to $3.9 million, reflecting heightened developmental activity.
